NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer

PURPOSE: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the anti-proliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ma, Cynthia X., Gao, Feng, Luo, Jingqin, Northfelt, Donald W., Goetz, Matthew, Forero, Andres, Hoog, Jeremy, Naughton, Michael, Ademuyiwa, Foluso, Suresh, Rama, Anderson, Karen S., Margenthaler, Julie, Aft, Rebecca, Hobday, Timothy, Moynihan, Timothy, Gillanders, William, Cyr, Amy, Eberlein, Timothy J., Hieken, Tina, Krontiras, Helen, Guo, Zhanfang, Lee, Michelle V., Spies, Nicholas C., Skidmore, Zachary L., Griffith, Obi L., Griffith, Malachi, Thomas, Shana, Bumb, Caroline, Vij, Kiran, Bartlett, Cynthia Huang, Koehler, Maria, Al-Kateb, Hussam, Sanati, Souzan, Ellis, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555232/
https://ncbi.nlm.nih.gov/pubmed/28270497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3206
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados